Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71265 ↗At a glance
Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2026. Written by Fatima Nari and 3 co-authors. Institution: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Major MEDLINE topics: Diabetes Mellitus, Type 2, Succinates, Aspirin, Blood Viscosity. 39 references. Funded by: Daewoong Pharmaceutical Company.
Topics: Diabetes mellitus
Abstract (original language)
Background
Whole blood viscosity (WBV) is associated with impaired microvascular circulation and cardiovascular risk in patients with Type 2 diabetes mellitus (T2DM) and peripheral artery disease (PAD). This study investigated the efficacy and safety of sarpogrelate compared with aspirin on WBV in patients with T2DM and PAD.
Methods
This randomised, open‐label clinical trial enrolled adults with T2DM and PAD. A total of 66 participants were randomised to aspirin ( n = 33) or sarpogrelate ( n = 33) for 24 weeks. The primary endpoint was change in diastolic WBV at a shear rate of 1 s −1 from baseline to week 24. Secondary endpoints included tissue oxygen delivery index, pain visual analogue scale (VAS) and cold sensation scores.
Results
After 24 weeks, diastolic WBV did not decrease significantly in both groups (sarpogrelate group: 31.91 ± 7.83 to 30.76 ± 7.08, mean change, −1.15 ± 9.25; p = 0.509; aspirin group: 33.32 ± 8.86 to 32.12 ± 9.60, mean change, −1.20 ± 8.36; p = 0.432). VAS scores improved significantly in both groups (mean change, −9.09 ± 18.09; p = 0.007 for sarpogrelate; −6.13 ± 16.47; p = 0.047 for aspirin), with no between‐group difference. Cold sensation scores improved only in the sarpogrelate group (mean change, −0.21 ± 0.55; p = 0.033 vs. −0.23 ± 0.85; p = 0.147 for aspirin group), with no between‐group difference.
Conclusion
In patients with T2DM and PAD, sarpogrelate did not significantly improve WBV compared with aspirin. VAS scores and cold sensation improved significantly within the sarpogrelate group with no between‐group difference.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID profiles: Jooyeop Lee, Soo Lim
Funding
- Daewoong Pharmaceutical Company
Cite
APA
Nari, F., Lee, J., Kim, J., & Lim, S. (2026). Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71265
Vancouver
Nari F, Lee J, Kim J, Lim S. Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71265
BibTeX
@article{Nari2026,
author = {Nari, Fatima and Lee, Jooyeop and Kim, Joohee and Lim, Soo},
title = {Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71265}
}
EUVIMED